Stock Events

Stock Events

Virax Biolabs Group 

$2.63
69
+$0.07+2.54% 19:56 Today
+$0.00+0.15%21:01After hours

Statistics

Day High
2.64
Day Low
2.55
52W High
21.75
52W Low
2.5
Volume
21,708
Avg. Volume
1,798,149
Mkt Cap
2.09M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2DecExpected
Q4 2023
Q2 2024
Q3 2024
Q2 2025
Q3 2025
Q2 2026
Next
-12.25
-11.92
-11.58
-11.25
Expected EPS
N/A
Actual EPS
N/A

Financials

-41,866.67%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
12,000Revenue
-5.02MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VRAX. It's not an investment recommendation.
NVIDIA
17
NVDA
Amazon
16
AMZN
Microsoft
14
MSFT
Tesla
13
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech SE is a competitor because it also focuses on developing and commercializing immunotherapies for infectious diseases, similar to Virax Biolabs' focus on viral diagnostics and immune health.
Moderna
MRNA
Mkt Cap55.09B
Moderna, Inc. is involved in the development of mRNA vaccines for infectious diseases, competing directly with Virax Biolabs' efforts in viral diagnostics and vaccine-related research.
Novavax
NVAX
Mkt Cap1.53B
Novavax, Inc. competes in the development of vaccines for infectious diseases, directly challenging Virax Biolabs' market in viral diagnostics and immune response solutions.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a broad portfolio in vaccines and therapeutics for infectious diseases, making it a competitor to Virax Biolabs, especially in the COVID-19 and other viral vaccine spaces.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson operates in the research and development of vaccines, including for viral infections, positioning it as a competitor to Virax Biolabs in the field of infectious disease prevention.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline plc works on vaccines and therapeutics for infectious diseases, competing with Virax Biolabs in the area of viral diagnostics and vaccine development.
Abbott Laboratories
ABT
Mkt Cap194.62B
Abbott Laboratories offers diagnostics and medical devices for infectious diseases, including viral infections, making it a competitor in the diagnostics space where Virax Biolabs operates.
QuidelOrtho
QDEL
Mkt Cap1.01B
Quidel Corporation specializes in diagnostic solutions for infectious diseases, directly competing with Virax Biolabs in the development of tests and diagnostics for viruses.
Thermo Fisher Scientific
TMO
Mkt Cap230.05B
Thermo Fisher Scientific Inc. provides a wide range of analytical instruments and diagnostic tools, including for infectious diseases, competing with Virax Biolabs in the diagnostics market.

About

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Show more...
CEO
James Foster
Employees
26
Country
Cayman Islands
ISIN
KYG9495L1335

Listings

BOATS
BOATS
VRAX.BOATS
XNAS
US
VRAX

0 Comments

Share your thoughts

FAQ

What is Virax Biolabs Group stock price today?▼
The current price of VRAX is $2.63 USD — it has increased by +2.54% in the past 24 hours. Watch Virax Biolabs Group stock price performance more closely on the chart.
What is Virax Biolabs Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Virax Biolabs Group stocks are traded under the ticker VRAX.
Is Virax Biolabs Group stock price growing?▼
VRAX stock has fallen by -6.91% compared to the previous week, the month change is a -11.91% fall, over the last year Virax Biolabs Group has showed a -82.7% decrease.
What is Virax Biolabs Group market cap?▼
Today Virax Biolabs Group has the market capitalization of 2.09M
When is the next Virax Biolabs Group earnings date?▼
Virax Biolabs Group is going to release the next earnings report on December 02, 2026.
What is Virax Biolabs Group revenue for the last year?▼
Virax Biolabs Group revenue for the last year amounts to 12,000 USD.
What is Virax Biolabs Group net income for the last year?▼
VRAX net income for the last year is -5.02M USD.
How many employees does Virax Biolabs Group have?▼
As of September 04, 2026, the company has 26 employees.
In which sector is Virax Biolabs Group located?▼
Virax Biolabs Group operates in the Health & Wellness sector.
When did Virax Biolabs Group complete a stock split?▼
The last stock split for Virax Biolabs Group was on June 26, 2026 with a ratio of 1:25.
Where is Virax Biolabs Group headquartered?▼
Virax Biolabs Group is headquartered in Lanarkshire, Cayman Islands.